Navigation Links
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Date:4/1/2008

IRVINE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported topline results of a clinical trial of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once-daily) 0.18% formulation, a new formulation of ISTA's ocular, non- steroidal anti-inflammatory agent. The findings demonstrated equivalence between the 0.18% formulation and ISTA's 0.09% formulation of Xibrom given once daily in achieving the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery. The data also showed no statistically significant difference between the two formulations in achieving the secondary efficacy endpoints of elimination of ocular pain and mean reduction of markers of inflammation (inflammatory cells and flare). In addition, the results indicated both formulations of bromfenac produced a low overall incidence of ocular adverse events.

"We undertook this trial in connection with our Xibrom QD NDA application, which was submitted to the FDA in December 2007. The nearly identical performance of the two concentrations was unexpected and inconsistent with the previously available data. The results suggest the 0.09% formulation is near the top of the dose-response curve," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "Our next steps are to complete the data analysis and speak with the FDA to determine a possible path forward, as well as consider other options in terms of new Xibrom products. Part of our discussions will be to review the possibility of a label change for the currently marketed 0.09% formulation of Xibrom so that it can be administered once-daily."

Conference Call

ISTA will host a conference call
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
8. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
11. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  BiOptix is pleased to announce the ... President of Chemistry and Biochemistry. Scott joins the company after ... and Amgen throughout the course of his nearly 20 ... "Scott is a nationally recognized thought leader in the ...
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
(Date:1/22/2015)... OAKS, Calif. , Jan. 22, 2015  Amgen (NASDAQ: ... and full year 2014 financial results on Tuesday, Jan. 27, 2015, ... be followed by a conference call with the investment community at ... Robert A. Bradway , chairman and chief executive officer, and ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to ... Pharmacy Services at North Carolina State’s College of Veterinary ... Beal Award for Distinguished Volunteer Service—the organization’s highest award. ... contributions of volunteer experts to direct its work to ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located in ... number one best large hotel for families in the United ... annual Travelers’ Choice Awards. , TripAdvisor represents the world’s ... to millions of unbiased and honest traveler reviews. The best ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... phase of trail and make soon be available and provide ... virus and the present vaccine protects against three strains of ... makes one feel really ill. In addition, flu can have ... average 10 to 20% of the world's population is infected ...
... University of North Carolina have identified a protein that ... protein, CIB1, or calcium and integrin-binding protein 1, was ... platelet protein that may play a role in clotting. ... functions that allow processes such as fetal development, new ...
... of morbidity and mortality in India. An attempt to formulate// ... many young lives, is worth the expense., , India ... a new vaccine for a deadly form of diarrhoea that ... been accelerated after phase I clinical trials showed up to ...
... from Johns Hopkins, the University of Arkansas, Worcester Polytechnic ... a new way to examine the fossils of our ... through the ages and why. ,By comparing teeth ... Paranthropus robustus, the researchers confirm previous evidence that A. ...
... significant health problems to be tackled despite significant medical// ... diet could help in improving resistance in Type II ... protein hydrolysate and amino acid mixture with carbohydrates increases ... help individuals control their blood sugar levels after a ...
... are those days when drinking was considered to be forbidden. ... ,A new research has found that drinking is ... have been reported to have better verbal skills, memory and ... drinking spectrum. Moderate drinkers not only performed the best but ...
Cached Medicine News:Health News:New Flu Vaccine Can Give Lifetime Protection 2Health News:Identified Protein To Inhibit Cell Migration 2Health News:Scientists Develop New Technology To Find About Human Ancestors’ Teet 2Health News:Increasing Insulin Response In Type 2 Diabetics With New Protein Mixture 2Health News:Yet Another Reason To Celebrate Drinking 2
... Horizon Cardiology Hemo is a comprehensive ... for the cath lab. Patient ... cardiac images and procedural information all ... patient record, eliminating repetitive data entry. ...
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
Data Trol™ Normal Control Serum provides the laboratory with vital information on the performance of clinical chemistry assays in the Normal range....
... is intended for monitoring the accuracy and precision ... for in vitro diagnostic use only. Provided in ... offers up to ten days stability at 2 ... be used in accordance with the directions accompanying ...
Medicine Products: